

# Theranostic Radioisotope production Techniques with High Current Cyclotrons

RR Johnson\* (Univ British Columbia)


Karim Butalag (Team BEST)\_

William Gelbart (Advanced System Devices)

1. Concentrate on treating disease    Theranostics Background Information
2. IBS potential isotopes
3. Key cyclotron features
4. Key targetry features
5. Neutron production too.
6. Case examples
  1. Lu177
  2. BNCT


Summary

*\*sponsored by TeamBest*



68Ga-PSMA-11 PET/CT scans of patient A. Pretherapeutic tumor spread (A), restaging 2 mo after third cycle of  $^{225}\text{Ac-PSMA-617}$  (B), and restaging 2 mo after one additional consolidation therapy (C). Clemens Kratochwil et al. J Nucl Med 2016;57:1941-1944

# Ac<sup>225</sup> Details



Ac 225 decay chain.


Alpha Energy  
MeV

5.9  
6.3  
7.2  
8.5

nominal Range in  
Muscle  
46 uM


Nominal Injection Dosage

100 KBq/kgBW  
Or  
6 MBq (160 mCi)

**A Progression-free Survival****Lutathera Therapy**

Strosberg J et al. N Engl J Med 2017;376:125-135.

## Lutetium Details



Nominal Injection Dosage

7.4 MBq (200 mCi)

Range in water ~ 3 mm

# Theranostic Pairs

**isotope for image**      **isotope for therapy**

$^{64}\text{Cu}$  (12.7 h)       $^{67}\text{Cu}$  (2.6 d, 141 keV)

$^{44}\text{Sc}$  (3.9 h)       $^{47}\text{Sc}$  (3.3 d, 162 keV)

$^{86}\text{Y}$  (14.7 h)       $^{90}\text{Y}^*$  (2.7 d, 934 keV)

$^{68}\text{Ga}$  (1.1 h)       $^{67}\text{Ga}$  (3.3 d, 12 keV)

$^{72}\text{As}$  (26.0 h)       $^{76}\text{As}$  (26 h, 1070 keV)

$^{77}\text{As}^*$  (39 h, 225 keV)

*Need pairs but select carefully*

## Therapy

$^{211}\text{At}$   $t_{1/2} = 7.2$  h

$^{225}\text{Ac}$   $t_{1/2} = 10.0$  d

$^{223}\text{Ra}$   $t_{1/2} = 11.4$  d

$^{111}\text{In}$   $t_{1/2} = 2.81$  d

reaction	isotope for image
$^{64}\text{Ni}(\text{p},\text{n})^{64}\text{Cu}$ T=15 MeV	$^{64}\text{Cu}$ (12.7 h)
$^{44}\text{Ca}(\text{p},\text{n})^{44}\text{Sc}$ T=15MeV	$^{44}\text{Sc}$ (3.9 h)
$^{86}\text{Sr}(\text{p},\text{n})^{86}\text{Y}$ T=15 MeV	$^{86}\text{Y}$ (14.7 h)
$^{69}\text{Ga}(\text{p},2\text{n})^{68}\text{Ge}$ T=35 Mev	$^{68}\text{Ga}$ (1.1 h)
$^{68}\text{Zn}(\text{p},\text{n})^{68}\text{Ga}$ T=15 MeV	
$^{72}\text{Ge}(\text{p},\text{n})^{72}\text{As}$ T=15 MeV	$^{72}\text{As}$ (26.0 h)
$^{70}\text{Ge}(\text{p},\text{n})^{70}\text{As}$ T=15 (53min)	

**isotope for therapy****reaction** $^{67}\text{Cu}$  (2.6 d, 141 keV) $^{68}\text{Zn}(p,2p)^{67}\text{Cu}$  T=70MeV $^{47}\text{Sc}$  (3.3 d, 162 keV) $^{48}\text{Ti}(p,2p)^{47}\text{Sc}$  T= 70 MeV $^{90}\text{Y}^*$  (2.7 d, 934 keV)reactor or  $^{91}\text{Zr}(p,2p)$  T=70 $^{67}\text{Ga}$  (3.3 d, 12 keV) $^{68}\text{Zn}(p,2n)^{67}\text{Ga}$  T=45 MeV $^{76}\text{As}$  (26 h, 1070 keV) $^{76}\text{Ge}(p,n)^{76}\text{As}$  $^{77}\text{As}^*$  (39 h, 225 keV) $^{78}\text{Se}(p,2p)^{77}\text{As}$ 

Bi209 (li6,4n)Rn211

 $^{211}\text{At}$   $t_{1/2} = 7.2$  h


Bi209(alpha,2n) 35 MeV

 $^{225}\text{Ac}$   $t_{1/2} = 10.0$  d $^{226}\text{Ra}(p,2n)^{225}\text{Ac}$  T=35 MeV $^{223}\text{Ra}$   $t_{1/2} = 11.4$  d $^{232}\text{Th}$  p spallation 100 MeV  
beta decay of  $^{223}\text{Fr}$  and  $\text{Ra}^{226}$   
(p,alpha)reactionelectron conversion  $^{112}\text{Cd}(p,2n)$  $^{111}\text{In}$   $t_{1/2} = 2.81$  d

T=35 MeV




# Cu<sup>67</sup> Production




Yield is 30 MBq/uAhr at 70 MeV


isotopic abundance  
 Zn68 19%  
 Zn70 0.6%



Yield at 25 MeV is 5 MBq/uAhr




Yield at 40 MeV is 1.8 MBq/uAhr



# Key features for Medical Radioisotope Production with compact cyclotrons

Energy, intensity, targets



B15 PET  
15 MeV  
1000 (200)  $\mu$ A +  
Targets Radiochem


B25  
20-25 MeV  
1000 (400)  $\mu$ A +  
Targets Radiochem

B35 (28)  
15-35(28) MeV  
1000(400)  $\mu$ A  
Targets Radiochem


B70  
35-70 MeV  
1000  $\mu$ A  
Targets Radiochem

Extractor for high current operation

Reduces cyclotron bunker footprint



Extractor mechanism holds 21 foils



Foil lifetime 20,000  $\mu\text{Ahrs}$   
@ 1000  $\mu\text{A}$  is 20 hours.


# Solid Target Station ... 50 kW

Send receive station


collimator


Front View

Back View













Targetry requirements



**Target Substrate**  
copper





Temperature distribution on  
target with 42.5 kW on target  
and 7.5 kW on collimator

40 L/min water flow


# Landing terminal

Targetry requirements





# 50 kW Beam Dump Assembly – Cut Through Vertical Symmetry Axis



## Lesson

**Target station and Beam stop tolerate 1 mA operation**  
and are engineered for remote repair and access

## Applications

**Use direct reaction when possible**

Example  $Y^{177}$  production

**Apply neutron production when needed**

Example BNCT

Neutron production


# **Case Study    $\text{Lu}^{177}$**

**$Y^{177}$  production estimate**

**$Hf^{178}$  (p,2p)  $Lu^{177}$**

Thick target yield  
estimate

Yield = 7 MBq/uA hr



Production yield estimate  $\sim 100\text{GB /day} = 2.6 \text{ Ci/day}$   
(700uA, 20 hrs)

Recall unit therapy dose is 200 mCi or 13 therapy doses

Reactor estimate is  $\sim 500 \text{ GB/day/mg}$

Dash et al., Nucl Med Mol Imaging (2015) 49

**To Do** for cyclotrons: Cross section, Contaminants, Specific Activity  
Etc, etc,etc


# Case Study

## Boron Neutron Capture Therapy



# Neutron production Target: Material selection

Target	Melting Point (°C)	Boiling Point (°C)	Thermal conductivity (W/mK)	Neutron yield (n/s mA)	Gamma-ray per neutron
Li	180	1340	84.7	1.14e14	0.09
W	3422	5555	174	9.63e14	1.39
Ta	3017	5448	57.5	1.25e14	0.93
Be	1278	2974	201	1.90e14	0.02



Lower Gamma  
production

Better Thermal  
conductivity

Higher Melting  
point

Beryllium is our preferred target

# Neutron production Target

**MODEL**



Proton Beam



Beryllium target

Simulations with MCNP6





$1.90 \times 10^{14}$  n/s at 30 MeV, 1mA

Over the whole  
solid angle

$\text{Be9(p,n)B9}$

# Beryllium Target inconvenients

Beryllium has low hydrogen solubility



**Insert layer of Palladium to adsorb the hydrogen!**

Beryllium

Palladium

Union of Compact Accelerator-Driven Neutron Sources I & II

Target Performance at the Low Energy Neutron Source

T. Rinckel<sup>\*a</sup>, D. V. Baxter<sup>a</sup>, J. Doskow<sup>a</sup>, P. E. Sokol<sup>a</sup>, and T. Todd<sup>a</sup>

<sup>a</sup>Indiana University Center for Exploration of Energy and Matter, 2401 Milo B. Sampson Lane, Bloomington, IN 47408, USA

# Irradiation at 25 MeV

**Simulations performed by  
MCNP6**

Proton beam energy 25MeV


Target thickness: 3.97mm

Target radius: 2.5cm


Pd Layer: 200 um

Cu cooling bulk: 2cm


Proton Beam






Neutron spectrum from beryllium target irradiation with  
25 MeV protons, 1 mA



# Neutron beam shaper for BNCT



# Adjust beam shaper material and geometry to obtain legitimate spectrum




Simulations by MCNP6

A 25 MeV cyclotron may be enough



Still working on it TBA



[T. Mutsumoto et al 2010]

## Summary

**Theranostics** are giving results but there must be care

**Cyclotrons and their targets** now have high current capability and there is **engineering for high activity** handling.

Two case studies

**Lu<sup>177</sup> may be competitive with reactor production.**

Depends on real cross section and specific activity

**BNCT**      there needs more beam shaping development.